|

Setidegrasib Clinical Trials

3 actively recruiting trials across 3 locations

▲ +1 trial since June 2026

Also known as: ASP3082

Pipeline

Phase 1: 1Phase 3: 2

Top Sponsors

  • Astellas Pharma Global Development, Inc.2
  • Astellas Pharma Inc1

Indications

  • Cancer3
  • Metastatic Pancreatic Adenocarcinoma1
  • Metastatic Pancreatic Cancer1
  • Non-small Cell Lung Cancer (NSCLC)1
  • Pancreatic Cancer1

Fort Smith, Arkansas1 trial

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Mercy Cancer Center

Phase 3

Duarte, California1 trial

A Study of ASP3082 in Adults With Advanced Solid Tumors

City of Hope National Medical Center

Phase 1

Glendale, California1 trial

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

Oncura Health d.b.a.Los Angeles Cancer Network

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.